Symposium on Advanced Wound Care: Regenative Labs to Present Its Groundbreaking Wharton’s Jelly Studies

0
133

Summation

  • Regenative Labs (Regenative), a leading provider of regenerative medicine solutions, announced that it will present two scientific studies demonstrating the efficacy of Wharton’s jelly allografts in complicated post-surgical wounds and late-stage sacral decubitus ulcers at the Symposium on Advanced Wound Care (SAWC) conference.
  • The 2023 event is co-located with the Diabetic Limb Salvage (DLS) conference to provide the latest education on the prevention and management of wound care, current scientific findings, and the most up-to-date limb salvage techniques.
  • The patient’s wound had failed to close after eight weeks of conservative treatment, but after receiving a single dose of Wharton’s jelly and twelve hyperbaric oxygen therapy visits, the wound healed entirely with 100 percent epithelialization overlying granulation tissue.

Regenative Labs (Regenative), a leading provider of regenerative medicine solutions, announced that it will present two scientific studies demonstrating the efficacy of Wharton’s jelly allografts in complicated post-surgical wounds and late-stage sacral decubitus ulcers at the Symposium on Advanced Wound Care (SAWC) conference.

Regenative’s first study showcases the successful use of its Wharton’s jelly flowable perinatal tissue allografts for a patient who experienced postoperative wound dehiscence after undergoing a lower body lift, breast reduction, and nipple-areolar transplant. The patient’s wound had failed to close after eight weeks of conservative treatment, but after receiving a single dose of Wharton’s jelly and twelve hyperbaric oxygen therapy visits, the wound healed entirely with 100 percent epithelialization overlying granulation tissue. The case study demonstrates the potential of Wharton’s jelly allografts in improving patient outcomes by offering an alternative to conventional treatment methods.

Regenative’s second study presents two patients with stage IV sacral decubitus ulcers. Both patients received six Wharton’s jelly applications and standard wound dressing during the study. The first patient with a ten-year-old wound experienced a 94 percent decrease in wound volume despite noncompliant at-home care. The second patient achieved a 100 percent decrease in wound volume compared to previous 30 months of failed conservative treatment. This study provides grounds for future research into the preventative application of Wharton’s jelly to stage II ulcers or earlier.

“We are excited to present these two groundbreaking studies at the SAWC conference,” said Tyler Barrett, CEO of Regenative Labs. “These results demonstrate the potential of Wharton’s jelly allografts in improving patient outcomes. We believe that these findings will have a significant impact on the field of regenerative medicine and wound care,” Barrett concluded.

Regenative Labs will present these studies at SAWC Spring | WHS, which will be held April 26–30 in National Harbor, Maryland. The 2023 event is co-located with the Diabetic Limb Salvage (DLS) conference to provide the latest education on the prevention and management of wound care, current scientific findings, and the most up-to-date limb salvage techniques.

For more information about the studies or to speak with one of its authors, please contact Regenative Labs on their website.